Table 2.

Univariate outcomes of patients receiving BEAM conditioning regimen and autologous HCT for DLBCL during 2003–2017

	BEAM (N = 667)		R-BEAM (N = 195)
Outcomes	N Eval	Prob (95% CI)	N Eval	Prob (95% CI)	p-value
Neutrophil recovery	665		193		0.18
30-day		99 (98–100)%		98 (96–100)%	0.50
Platelet recovery	663		192		0.72
100-day		97 (96–98)%		97 (94–99)%	0.91
Non-relapse mortality	667		195		0.12
1-year		5 (3–6)%		6 (3–10)%	0.44
4-year		9 (7–11)%		11 (7–16)%	0.39
Relapse/progression	667		195		0.25
1-year		31 (28–35)%		28 (22–35)%	0.41
4-year		44 (40–48)%		41 (33–48)%	0.40
Progression-free survival	667		195		0.75
1-year		64 (60–68)%		65 (59–72)%	0.69
4-year		47 (43–51)%		48 (41–56)%	0.77
Overall survival	667		195		0.77
1-year		78 (74–81)%		81 (75–86)%	0.33
4-year		61 (57–65)%		58 (51–65)%	0.54

Abbreviations: BEAM: carmustine, etoposide, cytarabine and melphalan; R-BEAM: rituximab +BEAM; N Eval: number evaluated; Prob: probability; HCT: hematopoietic cell transplantation; DLBCL: diffuse large B cell lymphoma